Citations

Clear

4847 citation(s) found for "Tu, Eric".

Rapid Molecular Microbiologic Diagnosis of Prosthetic Joint Infection
Cazanave, Charles , Greenwood‐Quaintance, Kerryl E. , Hanssen, Arlen D. , Karau, Melissa J. , Schmidt, Suzannah M., Urena, Eric O. Gomez, Mandrekar, Jayawant N. , Osmon, Douglas R. , Lough, Lindsay E., Pritt, Bobbi S. , Steckelberg, James M., Patel, Robin , Patel, Robin , Pritt, Bobbi S

Mayo Clinic

Journal of Clinical Microbiology | May 9, 2013 | Volume: 51 | Issue: 7 | Pages: 2280-2287

10.1128/jcm.00335-13 | PMID 23658273 Get It

ABSTRACT We previously showed that culture of samples obtained by prosthesis vortexing and sonication was more sensitive than tissue culture for prosthetic joint infection (PJI) diagnosis. Despite improved sensitivity, culture-negative cases remained; furthermore, culture has a long turnaround time. We designed a genus-/group-specific rapid PCR assay panel targeting PJI bacteria and applied it to samples obtained by vortexing and sonicating explanted hip and knee prostheses, and we compared the results to those with sonicate fluid and periprosthetic tissue culture obtained at revision or resection arthroplasty. We studied 434 subjects with knee ( n = 272) or hip ( n = 162) prostheses; using a standardized definition, 144 had PJI. Sensitivities of tissue culture, of sonicate fluid culture, and of PCR were 70.1, 72.9, and 77.1%, respectively. Specificities were 97.9, 98.3, and 97.9%, respectively. Sonicate fluid PCR was more sensitive than tissue culture ( P = 0.04). PCR of prosthesis sonication samples is more sensitive than tissue culture for the microbiologic diagnosis of prosthetic hip and knee infection and provides same-day PJI diagnosis with definition of microbiology. The high assay specificity suggests that typical PJI bacteria may not cause aseptic implant failure.
A Genome‐Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium
Tang, Weihong , Heit, John A. , Morange, Pierre‐Emmanuel , Pankratz, Nathan , Leebeek, Frank W.G. , Paré, Guillaume , Tzourio, Christophe , Basu, Saonli , Rose, Lynda M., Armasu, Sebastian M. , Lumley, Thomas, Heckbert, Susan R. , Uitterlinden, André G. , Lathrop, Mark, Cushman, Mary , Hofman, Albert , Lambert, Jean‐Charles , Glazer, Nicole L. , Pankow, James S. , Witteman, Jacqueline C.M., Amouyel, Philippe , Bis, Joshua C. , Bovill, Edwin G., Kong, Xiaoxiao , Boerwinkle, Eric , Trégouët, David‐Alexandre , Loth, Daan W. , Stricker, Bruno H. , Folsom, Aaron R. , Smith, Nicholas L. , Teichert, Martina , Chasman, Daniel I. , Guo, Li , Andrade, Mariza de , Psaty, Bruce M. , Ruiter, Rikje , Rice, Kenneth , Tracy, Russell P. , Rotter, Jerome I. , Ridker, Paul M. , Amouyel, Philippe , Tzourio, Christophe , Pankratz, Nathan , Pankow, James S , Tang, Weihong , Paré, Guillaume

Mayo Clinic

Genetic Epidemiology | May 5, 2013 | Volume: 37 | Issue: 5 | Pages: 512-521

10.1002/gepi.21731 | PMID 23650146 Get It

ABSTRACTVenous thromboembolism (VTE) is a common, heritable disease resulting in high rates of hospitalization and mortality. Yet few associations between VTE and genetic variants, all in the coagulation pathway, have been established. To identify additional genetic determinants of VTE, we conducted a two‐stage genome‐wide association study (GWAS) among individuals of European ancestry in the extended cohorts for heart and aging research in genomic epidemiology (CHARGE) VTE consortium. The discovery GWAS comprised 1,618 incident VTE cases out of 44,499 participants from six community‐based studies. Genotypes for genome‐wide single‐nucleotide polymorphisms (SNPs) were imputed to approximately 2.5 million SNPs in HapMap and association with VTE assessed using study‐design appropriate regression methods. Meta‐analysis of these results identified two known loci, in F5 and ABO. Top 1,047 tag SNPs (P ≤ 0.0016) from the discovery GWAS were tested for association in an additional 3,231 cases and 3,536 controls from three case‐control studies. In the combined data from these two stages, additional genome‐wide significant associations were observed on 4q35 at F11 (top SNP rs4253399, intronic to F11) and on 4q28 at FGG (rs6536024, 9.7 kb from FGG; P < 5.0 × 10−13 for both). The associations at the FGG locus were not completely explained by previously reported variants. Loci at or near SUSD1 and OTUD7A showed borderline yet novel associations (P < 5.0 × 10−6) and constitute new candidate genes. In conclusion, this large GWAS replicated key genetic associations in F5 and ABO, and confirmed the importance of F11 and FGG loci for VTE. Future studies are warranted to better characterize the associations with F11 and FGG and to replicate the new candidate associations.
Risk Factors for Excessive Anticoagulation Among Hospitalized Adults Receiving Warfarin Therapy Using a Pharmacist‐Managed Dosing Protocol
Berg, Tamara M., O’Meara, John G. , Ou, Narith N., Daniels, Paul R. , Moriarty, James P. , Bergstrahl, Eric J., Dierkhising, Ross , Manning, Dennis M.

Mayo Clinic

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy | April 26, 2013 | Volume: 33 | Issue: 11 | Pages: 1165-1174

10.1002/phar.1280 | PMID 23625787 Get It

Study ObjectiveTo identify specific risk factors for excessive anticoagulation, defined as an international normalized ratio (INR) higher than 5, in hospitalized adults receiving warfarin therapy using a pharmacist‐managed dosing protocol.DesignRetrospective nested case‐control study.SettingLarge academic tertiary care medical center.PatientsHospitalized nonsurgical patients 18 years or older who received at least one dose of warfarin according to the pharmacist‐managed protocol from January 1, 2009, to January 31, 2012, were included. Patients who experienced an INR higher than 5 were designated as case patients; those who received warfarin for at least as many days as the case patients but who did not experience an INR more than 5 were deemed control patients. Controls were matched to cases in a 2:1 ratio by age, sex, INR goal, and type of warfarin therapy (new start or continuation).Measurements and Main ResultsA total of 87 case patients were matched to 174 controls. Ten different hypothesized risk factors were examined. Two variables, severity of illness score (odds ratio [OR] 4.89, p<0.001) and poor nutritional status (OR 4.27, p<0.001), demonstrated strong independent associations with risk of excessive anticoagulation. Administration of interacting drugs that highly potentiate warfarin's effect (OR 2.26, p=0.011) and concurrent diarrheal illness (OR 4.75, p<0.001) also displayed a statistically significant risk for excessive anticoagulation.ConclusionEven in a highly standardized system for warfarin dosing by a pharmacist‐managed protocol, higher disease severity and poor nutritional status placed hospitalized patients at greater risk of experiencing excessive anticoagulation. In addition, administration of interacting drugs that highly potentiate warfarin's effect or the occurrence of diarrheal illness may predict increased risk.
Fibrillar amyloid correlates of preclinical cognitive decline
Stonnington, Cynthia M. , Chen, Kewei , Lee, Wendy , Locke, Dona E.C. , Dueck, Amylou C., Roontiva, Auttawut, Fleisher, Adam , Caselli, Richard J. , Reiman, Eric M. , Dueck, Amylou C. , Liu, Xiaofen , Dueck, A. C. , Locke, Dona E C

Mayo Clinic

Alzheimer's & Dementia | April 16, 2013 | Volume: 10 | Issue: 1 | Pages: No page available

10.1016/j.jalz.2013.01.009 | PMID 23583233 Get It

AbstractBackgroundIt is not known whether preclinical cognitive decline is associated with fibrillar β‐amyloid (Aβ) deposition irrespective of apolipoprotein E (APOE) ε4 status.MethodsFrom a prospective observational study of 623 cognitively normal individuals, we identified all subjects who showed preclinical decline of at least 2 standard deviations beyond the decline of the entire group in memory or executive function. Fourteen decliners were matched by APOE ε4 gene dose, age, sex, and education with 14 nondecliners. Dynamic Pittsburgh compound B (PiB) positron emission tomography (PET) scans, the Logan method, statistical parametric mapping, and automatically labeled regions of interest were used to characterize and compare cerebral‐to‐cerebellar PiB distribution volume ratios (DVRs), reflecting fibrillar Aβ burden.ResultsAt P < .005 (uncorrected), decliners had significantly greater DVRs in comparison to nondecliners.ConclusionsAsymptomatic longitudinal neuropsychological decline is associated with subsequent increased fibrillar amyloid deposition, even when controlling for APOE ε4 genotype.
A Sequence-Based Variation Map of Zebrafish
Patowary, Ashok , Purkanti, Ramya , Singh, Meghna , Chauhan, Rajendra , Singh, Angom Ramcharan, Swarnkar, Mohit Kumar , Torroja, Carlos , Kocher, Jean‐Pierre , Clark, Karl J. , Klee, Eric W. , Ekker, Stephen C. , Scaria, Vinod , Sivasubbu, Sridhar , Singh, Naresh , Pandey, Vikas , Clark, Matthew D. , Stemple, Derek L. , Ekker, Stephen C , Clark, Karl J

Mayo Clinic

Zebrafish | April 16, 2013 | Volume: 10 | Issue: 1 | Pages: 15-20

10.1089/zeb.2012.0848 | PMID 23590399 Get It

Abstract Zebrafish ( Danio rerio ) is a popular vertebrate model organism largely deployed using outbred laboratory animals. The nonisogenic nature of the zebrafish as a model system offers the opportunity to understand natural variations and their effect in modulating phenotype. In an effort to better characterize the range of natural variation in this model system and to complement the zebrafish reference genome project, the whole genome sequence of a wild zebrafish at 39-fold genome coverage was determined. Comparative analysis with the zebrafish reference genome revealed approximately 5.2 million single nucleotide variations and over 1.6 million insertion–deletion variations. This dataset thus represents a new catalog of genetic variations in the zebrafish genome. Further analysis revealed selective enrichment for variations in genes involved in immune function and response to the environment, suggesting genome-level adaptations to environmental niches. We also show that human disease gene orthologs in the sequenced wild zebrafish genome show a lower ratio of nonsynonymous to synonymous single nucleotide variations.
Impact of Statin Use on Lipid Levels in Statin‐Naive Patients With Rheumatoid Arthritis Versus Non–Rheumatoid Arthritis Subjects: Results From a Population‐Based Study
Myasoedova, Elena , Gabriel, Sherine E., Green, Abigail B., Matteson, Eric L. , Crowson, Cynthia S. , Myasoedova, Elena

Mayo Clinic

Arthritis Care & Research | April 16, 2013 | Volume: 65 | Issue: 10 | Pages: 1592-1599

10.1002/acr.22029 | PMID 23592565 Get It

ObjectiveTo examine lipid profiles among statin‐naive patients with rheumatoid arthritis (RA) and those without RA before and after the initiation of statins.MethodsInformation regarding lipid measures and statin use was gathered in a population‐based incident cohort of patients with RA (1987 American College of Rheumatology criteria first met between January 1, 1988 and January 1, 2008) and in a cohort of non‐RA subjects from the same underlying population. Only patients with no prior history of statin use were included.ResultsThe study included 161 patients with RA (mean age 56.3 years, 57% female) and 221 non‐RA subjects (mean age 56.0 years, 66% female). Prior to the start of statins, the levels of total cholesterol and low‐density lipoprotein (LDL) cholesterol were lower in the RA versus the non‐RA cohort (P < 0.001 and P = 0.003, respectively). The absolute and percentage change in LDL cholesterol after at least 90 days of statin use tended to be smaller in the RA versus the non‐RA cohort (P = 0.03 and P = 0.09, respectively). After at least 90 days of statin use, patients with RA were less likely to achieve therapeutic goals for LDL cholesterol than the non‐RA subjects (P = 0.046). Increased erythrocyte sedimentation rate (ESR) at baseline (odds ratio 0.47, 95% confidence interval 0.26–0.85) was associated with lower likelihood of achieving therapeutic LDL goals.ConclusionPatients with RA had lower total cholesterol and LDL cholesterol levels before statin initiation and lower likelihood of achieving therapeutic LDL goals following statin use than the non‐RA subjects. Some RA disease characteristics, in particular ESR at baseline, may have an adverse impact on achieving therapeutic LDL goals.
The USPSTF Recommendation Statement on Coronary Heart Disease Risk Assessment
Matteson, Eric L. , Crowson, Cynthia S., Gabriel, Sherine E., Crowson, Cynthia S., Gabriel, Sherine E.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 152 | Issue: 6 | Pages: 405

10.7326/0003-4819-152-6-201003160-00018 | PMID 20231580 Get It

Narrative Review: Reperfusion Strategies for ST-Segment Elevation Myocardial Infarction
Ting, Henry H. , Rihal, Charanjit S. , Yang, Eric H. , Rihal, Charanjit S.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 145 | Issue: 8 | Pages: 610-617

10.7326/0003-4819-145-8-200610170-00010 | PMID 17043342 Get It

A Fatal Case of Babesiosis in Missouri: Identification of Another Piroplasm That Infects Humans
Herwaldt, Barbara L., Persing, David H., Precigout, Eric A., Goff, W. L., Mathiesen, Dane A., Taylor, Philip W., Eberhard, M. L., Gorenflot, Andre F., Persing, David H., Precigout, Eric A., Goff, W. L., Mathiesen, Dane A., Taylor, Philip W., Eberhard, M. L., Gorenflot, Andre F.

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 124 | Issue: 7 | Pages: 643-650

10.7326/0003-4819-124-7-199604010-00004 | PMID 8607592 Get It

A Multidimensional Index and Staging System for Idiopathic Pulmonary Fibrosis
Ley, Brett, Ryerson, Christopher J. , Lee, Joyce , Poletti, Venerino , Buccioli, Matteo , Elicker, Brett M. , Jones, Kirk D. , King, Talmadge E. , Collard, Harold R. , Vittinghoff, Eric , Ryu, Jay H. , Tomassetti, Sara , Lee, Joyce S

Mayo Clinic

Annals of Internal Medicine | April 12, 2013 | Volume: 156 | Issue: 10 | Pages: 684-691

10.7326/0003-4819-156-10-201205150-00004 | PMID 22586007 Get It